Additionally, the rates of T2DM-related medication use—including use of sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, DPP4 inhibitors, and insulin—were similar between the SGLT2 inhibitor group and the control group (all ASDs < 0.1; Table 1). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.